SCHEMBL298305

SCHEMBL298305

CCc1c2[n+](cc3c(OC)c(OC)ccc13)CCc1cc3c(cc1-2)OCO3

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
P2RX7 Q99572 16/20 1.00
ALDH1A1 P00352 2/20 0.64
LMNA P02545 2/20 0.64
BCHE P06276 2/20 0.64
CYP3A4 P08684 2/20 0.64
CYP2D6 P10635 2/20 0.64
MAPT P10636 2/20 0.64
CHRM1 P11229 2/20 0.64
DRD2 P14416 2/20 0.64
TSHR P16473 2/20 0.64
ADRA2B P18089 2/20 0.64
ADRA2C P18825 2/20 0.64
RXRA P19793 2/20 0.64
DRD1 P21728 2/20 0.64
ACHE P22303 2/20 0.64
HTR2B P41595 2/20 0.64
HTT P42858 2/20 0.64
RAD52 P43351 2/20 0.64
EP300 Q09472 2/20 0.64
KCNH2 Q12809 2/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14513612 0.94 P2RX7 (0.89) P2RX7ALDH1A1LMNABCHECYP3A4
SCHEMBL14513590 0.93 P2RX7 (0.87) P2RX7
SCHEMBL14513605 0.91 P2RX7 (0.84) P2RX7ALDH1A1LMNABCHECYP3A4
SCHEMBL14924401 0.91 P2RX7 (0.82) P2RX7ALDH1A1LMNABCHECYP3A4
SCHEMBL14513608 0.90 P2RX7 (0.81) P2RX7ALDH1A1LMNABCHECYP3A4
SCHEMBL13814556 0.89 P2RX7 (0.81) P2RX7ALDH1A1LMNABCHECYP3A4
SCHEMBL13814544 0.89 P2RX7 (0.81) P2RX7ALDH1A1LMNABCHECYP3A4
SCHEMBL298959 0.89 P2RX7 (1.00) P2RX7ALDH1A1LMNABCHECYP3A4
Iodide SCHEMBL31537712 0.89 P2RX7 (1.00) P2RX7ALDH1A1LMNABCHECYP3A4
SCHEMBL297977 0.89 P2RX7 (0.81) P2RX7ALDH1A1LMNABCHECYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2427460-B1 NOVEL ISOQUINOLINE DERIVATIVES HOFFMANN LA ROCHE (CH) 2014-03-26 EP disclosed
EP-2427460-B1 NOVEL ISOQUINOLINE DERIVATIVES HOFFMANN LA ROCHE (CH) 2014-03-26 EP disclosed
US-8258149-B2 Isoquinoline derivatives HOFFMANN-LA ROCHE INC. (US) 2012-09-04 US disclosed
US-8258149-B2 Isoquinoline derivatives HOFFMANN-LA ROCHE INC. (US) 2012-09-04 US disclosed
EP-2427460-A1 NOVEL ISOQUINOLINE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2012-03-14 EP disclosed
WO-2010128061-A1 NOVEL ISOQUINOLINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2010-11-11 WO disclosed
US-20100286396-A1 NOVEL ISOQUINOLINE DERIVATIVES HOFFMANN-LA ROCHE, INC. 2010-11-11 US disclosed
US-20100286396-A1 NOVEL ISOQUINOLINE DERIVATIVES HOFFMANN-LA ROCHE, INC. 2010-11-11 US disclosed
EP-2070926-A1 13,13a-DIHYDROBERBERINE DERIVATIVES, THEIR PHARMACEUTICAL COMPOSITION AND USE Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) 2009-06-17 EP disclosed
US-20070098649-A1 Method and composition for controlling oral pathogens THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (IL) 2007-05-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100286396-A1 NOVEL ISOQUINOLINE DERIVATIVES CYP3A7, RAB7A, IPO7 P2RX7 669/4885ALDH1A1 881/4885LMNA 2964/4885
US-20070098649-A1 Method and composition for controlling oral pathogens BROX, NOP2, FBL P2RX7 2447/4885ALDH1A1 4776/4885LMNA 2749/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.